Prognostic Value of Glioma Cancer Stem Cell Isolation in Survival of Primary Glioblastoma Patients

• Main Authors: Byung Ho Kong (Author), Ju Hyung Moon (Author), Yong-Min Huh (Author), Jin-Kyoung Shim (Author), Ji-Hyun Lee (Author), Eui-Hyun Kim (Author), Jong Hee Chang (Author), Dong-Seok Kim (Author), Yong-Kil Hong (Author), Sun Ho Kim (Author), Su-Jae Lee (Author), Seok-Gu Kang (Author)
• Format: Book
• Published: Hindawi Limited, 2014-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1687-966X; 1687-9678; 10.1155/2014/838950
• Keywords: Internal medicine; RC31-1245
• Source: Stem Cells International, Vol 2014 (2014)

Cancer stem cells (CSCs) have been reported to be critical in the initiation, maintenance, and progression of cancers. The expression of stem cell markers, such as podoplanin (PDPN), CD133, and nestin, may have been correlated with malignant progression. However, the effects of CSCs and stem cell markers on clinical outcomes in cancer patients remain unclear. In this study, we assessed the prognostic roles of glioma CSCs (gCSCs) isolation and stem cell markers in patients with primary glioblastoma (pGBM). A cohort of 39 patients with pGBM was separated into two groups, those positive or negative for gCSCs, and the correlation between gCSC and patient survival was evaluated. We observed significantly different cumulative survival (P=0.045) when comparing patients positive for gCSCs patients and negative for gCSC. Among the patients positive for gCSCs, we observed no significant differences in survival between those whose gCSCs were each positive or negative for PDPN, CD133, or nestin. This study strongly supports the prognostic value of gCSCs isolation on the survival of patients with pGBM.